However, in a clinical trial using an LTR-driven gammaretroviral vector, progressive silencing of the transgene cassette compromised the therapeutic effects, and long-term marking was complicated by insertional upregulation of the MDS/EVI1 proto-oncogene, ultimately inducing a myelodysplastic syndrome [87,161,175]. Here, MECOM is linked to myelodysplastic syndrome.